Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced a milestone patient revision from a traditional sacral neuromodulation ...
During the panel discussion with behavioral health experts, Cavanagh, speaking in his role at Restore Brain, addressed one of ...
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
Theranica, a neuromodulation therapeutics company advancing clinically validated, drug-free treatments for idiopathic pain conditions, today announced that health insurance coverage for its ...
Boston Scientific executive discusses $533M Nalu Medical acquisition strategy and plans for peripheral nerve stimulation ...
Honor highlights international startup advancing non-invasive rehabilitation technology for people living with chronic spinal cord injury ExaStim® Stimulation System Pictured is the complete ExaStim® ...
At the 20th Annual Spine, Orthopedic + Pain Management-Driven ASC Conference, participants gathered to explore the latest advances in neuromodulation in ASCs and HOPDs. This session brought together a ...
Urinary retention without an identifiable urological cause presents a diagnostic and therapeutic challenge. Patients with nonobstructive chronic urinary retention usually have to rely on intermittent ...
The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results